A Review of the Mechanism of Cardiac Benefit of Sodium-Glucose Cotransporter 2 Inhibitors

Sodium-glucose cotransporter 2 inhibitor (SGLT2i) is a new type of hypoglycemic drug, which can reduce the excitability sympathetic nerve by regulating metabolism energy substrate, electrolyte, tissue fluid and circulating blood volume in ganglion, interfering with inflammation oxidative stress, offering protection to vascular endothelial cells, maintaining vasodilation function, pressure load myocardial metabolism, as well protecting cardiomyocytes cardiac function.